CytomX Therapeutics Inc
NASDAQ:CTMX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Stockmann Oyj Abp
OMXH:STOCKA
|
FI |
|
Fujian Star-net Communication Co Ltd
SZSE:002396
|
CN |
|
Z
|
Zhongmin Energy Co Ltd
SSE:600163
|
CN |
|
S
|
Sanbo Hospital Management Group Ltd
SZSE:301293
|
CN |
|
GFL Ltd
NSE:GFLLIMITED
|
IN |
|
Companhia Brasileira de Distribuicao SA
BOVESPA:PCAR3
|
BR |
|
C
|
CITIC Resources Holdings Ltd
HKEX:1205
|
HK |
|
Haci Omer Sabanci Holding AS
IST:SAHOL.E
|
TR |
CytomX Therapeutics Inc
Total Equity
CytomX Therapeutics Inc
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
CytomX Therapeutics Inc
NASDAQ:CTMX
|
Total Equity
$99m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
15%
|
CAGR 10-Years
-2%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Equity
-$3.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Equity
$22.7B
|
CAGR 3-Years
2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Equity
$8.7B
|
CAGR 3-Years
33%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-11%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Equity
$18.7B
|
CAGR 3-Years
10%
|
CAGR 5-Years
17%
|
CAGR 10-Years
35%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Equity
$31.3B
|
CAGR 3-Years
11%
|
CAGR 5-Years
23%
|
CAGR 10-Years
24%
|
|
CytomX Therapeutics Inc
Glance View
CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. The company is headquartered in South San Francisco, California and currently employs 174 full-time employees. The company went IPO on 2015-10-08. The firm is developing a class of investigational conditionally activated therapeutics, based on its Probody technology platform, for the treatment of cancer. Its Probody technology platform is designed to enable conditional activation of antibody-based drugs in the tumor microenvironment while minimizing drug activity in healthy tissues and in circulation. The company has utilized its multi-modality Probody platform to build a pipeline of therapeutics that encompasses six product candidates, four of which are in multiple Phase II clinical studies in nine cancer indications. The company includes the conditionally activated antibody-drug conjugates (ADCs) praluzatamab ravtansine (CX-2009, targeting CD166) and CX-2029 (targeting CD71), and the Probody immune CPIs pacmilimab (CX-072, targeting PD-L1) and BMS-986249 (targeting CTLA-4).
See Also
What is CytomX Therapeutics Inc's Total Equity?
Total Equity
99m
USD
Based on the financial report for Dec 31, 2025, CytomX Therapeutics Inc's Total Equity amounts to 99m USD.
What is CytomX Therapeutics Inc's Total Equity growth rate?
Total Equity CAGR 10Y
-2%
